pharmaphorum

OCTOBER 27, 2022

The Swiss biotech is seeking a priority review for vamorolone, which was licensed from US biotech ReveraGen BioPharma in 2020 after Santhera its former DMD therapy candidate idebenone failed clinical testing and was abandoned. Its lead drug has already claimed fast track and rare paediatric disease designations from the FDA.

FDA 86

FDA Side effects Biopharma Marketing 86

European Pharmaceutical Review

NOVEMBER 1, 2022

Putting pandemic-related factors aside, a significant portion of the heightened demand for CRO/CDMO services has been driven by VC-backed pharma and biopharma companies. Presently, VC-funded biotechs are sitting on 2-3 years of cash reserves and this will ultimately transfer through, in part, to contract services.

Pharma 52

Pharma Biopharma Marketing Networking 52

Pharmaceutical Technology

JANUARY 31, 2023

FDA director Robert Califf gave his prognosis for the pharma industry at this year’s JP Morgan Healthcare Conference in San Francisco over January 9–12. That leaves three years for pharma companies to prepare. This “skinny” bill passed just in time to continue funding the FDA, with few of the planned amendments.

FDA 52

FDA Prescription Medicine Biopharma 52

pharmaphorum

OCTOBER 31, 2022

Sen (pictured above) was barely in the new role before activist hedge fund Elliott Investment Management took what is reported to be a “substantial” stake in the group a couple of weeks ago, with market watchers now waiting to see if it will agitate for change. Excluding those, net income would have fallen 19%.

Biopharma 57

Biopharma Pharma Healthcare Healthcare 57

European Pharmaceutical Review

OCTOBER 11, 2022

The study produced by the University of Cambridge has indicated that pharmaceutical companies are increasingly leaning away from one-time transactions with contract research organisations (CRO), to preferred providers and multi-year strategic partnerships. For instance, in the US it takes on average 10 to 15 years and over $2.5

Management 80

Management Pharma Pharmaceutical Biopharma 80

European Pharmaceutical Review

DECEMBER 21, 2022

Fluoxetine was approved to treat depression 35 years ago. But in early 2022, the country’s health minister announced his approval of research into psychedelic therapies and increased funding for mental health research. For many indications, progress has been incremental. Psychedelic research, in particular, is gaining momentum. .

Food and Drug Administration 107

Food and Drug Administration Medicine Food Government 107

Eversana Intouch

FEBRUARY 23, 2023

Biopharma valuations are down, especially for public and earlier-stage companies. Clinical trial shutdowns in Russia and Ukraine have driven a slowdown and will affect the diversity and expense of clinical trials for years to come. Shifts in government healthcare policy and funding. Reduced VC funding. Formulary changes.

Marketing 52

Marketing Pharma Patients Insurance 52

Eversana Intouch

FEBRUARY 23, 2023

Biopharma valuations are down, especially for public and earlier-stage companies. Clinical trial shutdowns in Russia and Ukraine have driven a slowdown and will affect the diversity and expense of clinical trials for years to come. Shifts in government healthcare policy and funding. Reduced VC funding. Formulary changes.

Marketing 52

Marketing Pharma Patients Insurance 52

pharmaphorum

JANUARY 11, 2023

Despite the well-documented retreat from record levels of funding for digital health ventures during the pandemic, the sector remains resilient with regulatory filings and partnering activity well up in 2022 on the previous year. Roche tops biopharma partnering podium.

Biopharma 71

Biopharma Specialization Physicians Healthcare 71

European Pharmaceutical Review

AUGUST 24, 2023

This strategy shift did not occur overnight, but evolved in response to the changing biopharma landscape. Even among the leaders of the biopharma sector, few companies have a significant presence across these platforms, Baral highlighted.

Biopharma 80

Biopharma Pharmaceutical Pharma Medical 80

pharmaphorum

JANUARY 24, 2023

Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. Notable examples include a pair of 10-year alliances with mRNA specialists Moderna and BioNTech. Established trends are unfortunately firmly in the wrong direction.

Manufacturing 105

Manufacturing Medicine Government Pharmaceutical manufacturing 105

PM360

JUNE 16, 2023

Funding and access are not new topics of conversation in the rare disease space. Genzyme made headlines in the ’90s when it launched the enzyme replacement therapy Cerezyme for a then-unprecedented $300,000 per year. Cell and gene therapies (CGTs) marked a shift in the rare disease paradigm.

Marketing 98

Marketing Management Insurance Specialization 98

European Pharmaceutical Review

APRIL 25, 2023

The biopharmaceutical facility received €350 million in funding, the company’s largest single investment in Germany to date. “In For example, in the last business year, this has amounted to €5 billion, 47 percent alone in Germany. They will have capabilities to produce these substances from lab-scale to supply for clinical studies.

Biopharma 67

Biopharma Networking Pharmaceutical Management 67

Clarivate

MARCH 12, 2024

For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.

Government 52

Government Physicians Marketing Biopharma 52

European Pharmaceutical Review

OCTOBER 19, 2023

billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. This is not an effective strategy.

Food and Drug Administration 88

Food and Drug Administration Side effects Manufacturing Doctors 88